• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week

    12/30/25 8:48:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PRFX alert in real time by email

    AI-driven monitoring and analytics solutions addressing the growing demand for energy efficiency in large-scale solar and critical infrastructure projects across the Middle East.

    TEL AVIV, Israel, Dec. 30, 2025 /PRNewswire/ -- BladeRanger (TASE: BLRN), a provider of drone-based inspection, maintenance, and AI-driven analytics solutions for green energy and critical infrastructure, today announced its participation in Abu Dhabi Sustainability Week (ADSW), a leading global platform dedicated to sustainability, clean energy, and climate-related innovation.

    At the conference, BladeRanger will highlight its flagship platforms, including Solar Drone and their cooperation with DeepSolar platform of PainReform (NASDAQ:PRFX), which delivers advanced monitoring, analytics, maintenance and operational optimization for utility-scale solar assets and complex energy infrastructure.

    The Middle East continues to experience unprecedented investment in energy transition and digital infrastructure. In the UAE alone, long-term investments in hyperscale data centers and supporting energy systems are estimated at approximately $600 billion, significantly increasing the importance of efficiency, reliability, and performance optimization across solar and renewable assets.

    The conference brings together leading regional energy groups including ADNOC, TAQA, and Masdar, which manage large-scale, multi-gigawatt solar and renewable energy portfolios across the Middle East and international markets. BladeRanger held a series of meetings with representatives of these organizations earlier this month as part of its ongoing business development activities in the region.

    BladeRanger's participation in ADSW follows a series of strategic meetings held in Dubai, conducted in collaboration with PainReform, during which the company presented its advanced monitoring and analytics capabilities to regional stakeholders.

    Shmulik Yannay, Chief Executive Officer of BladeRanger, said: "The appetite we encountered in the UAE for BladeRanger's core technologies was very strong. Energy efficiency in green energy, and solar in particular, has become critically important, especially in light of the region's estimated $600 billion investment in hyperscale data center infrastructure. We believe that our participation in Abu Dhabi Sustainability Week will support meaningful progress in advancing BladeRanger's activities in the Emirates."

    BladeRanger views its participation in Abu Dhabi Sustainability Week as an important step in expanding its regional presence and strengthening relationships with energy-sector stakeholders focused on efficient, resilient, and sustainable energy systems.

    About BladeRanger

    BladeRanger (TASE: BLRN) is a technology company specializing in drone-based inspection, maintenance, and AI-driven analytics solutions for green energy and critical infrastructure. The company's technologies, including Deep Solar and Solar Drone, support improved operational efficiency, monitoring, and performance optimization for large-scale solar and energy assets. BladeRanger operates internationally and continues to expand its presence through strategic partnerships and market-focused initiatives.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of applicable securities laws. These statements include, but are not limited to, statements regarding BladeRanger's participation in Abu Dhabi Sustainability Week, regional expansion opportunities, market demand, and the expected benefits of the Company's technologies. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that may affect results include market conditions, regulatory developments, competitive dynamics, and other risks described in the Company's public filings. BladeRanger undertakes no obligation to update any forward-looking statements, except as required by law.

    Cision View original content:https://www.prnewswire.com/news-releases/bladeranger-to-showcase-advanced-green-energy-technologies-at-abu-dhabi-sustainability-week-302650696.html

    SOURCE BladeRanger

    Get the next $PRFX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRFX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRFX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Aviel Sigal

    3 - PRF Technologies Ltd. (0001801834) (Issuer)

    3/18/26 6:14:33 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Baron Ellen S

    3 - PRF Technologies Ltd. (0001801834) (Issuer)

    3/18/26 6:11:55 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Cohen-Arazi Efraim

    3 - PRF Technologies Ltd. (0001801834) (Issuer)

    3/18/26 6:09:44 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    SEC Filings

    View All

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    3/17/26 8:57:14 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    3/3/26 4:15:07 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PRF Technologies Ltd.

    6-K - PRF Technologies Ltd. (0001801834) (Filer)

    2/18/26 9:38:03 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements

    TEL AVIV, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") today announced a commercial collaboration agreement with Blade Ranger Ltd. (TASE: BLRN) designed to accelerate the commercial expansion of its DeepSolar platform across utility-scale solar portfolios. The commercial collaboration agreement is structured to support the introduction and negotiation of multiple large-scale commercial engagements for DeepSolar, each with a minimum scope of 150 megawatts (MW), representing significant potential enterprise-level deployments. Blade Ranger operates at the intersection of renewable energy development, asset optimization, and infrastr

    3/17/26 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy

    TEL AVIV, Israel, Feb. 18, 2026 (GLOBE NEWSWIRE) -- PRF Technologies Ltd. (NASDAQ:PRFX) ("PRF" or the "Company") (formerly "PainReform") today announced that its DeepSolar business unit has entered into a solar analytics services agreement with a subsidiary of EDF Group (Electricite' De France, France's Electric Company, one of the largest international energy companies), a global leader in renewable energy, relating to an operational, utility-scale solar power plant in Israel. This engagement represents the next phase of Deep Solar's previously announced strategy and a new commercial revenue opportunity—an important milestone following the recent launch of Smart TDD. Pursuant to the agre

    2/18/26 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base

    TEL AVIV, Israel, Feb. 11, 2026 (GLOBE NEWSWIRE) -- PRF Technologies (NASDAQ:PRFX) ("PRF" or the "Company"), through its DeepSolar™ AI-driven solar analytics business unit, today announced the signing of a software-as-a-service (SaaS) agreement with Shikun & Binui Energy for the deployment of DeepSolar at the 71 megawatt (MW) Satu Mare photovoltaic site in Romania. The Satu Mare project is a utility-scale solar plant owned and operated by Shikun & Binui Energy. Under the agreement, DeepSolar will provide continuous analytics and performance monitoring designed to enhance operational visibility, support proactive asset management, and enable data-driven decision-making throughout the proje

    2/11/26 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/14/24 4:25:42 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PainReform Ltd.

    SC 13G/A - PAINREFORM LTD. (0001801834) (Subject)

    11/13/24 11:18:32 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by PainReform Ltd.

    SC 13D/A - PAINREFORM LTD. (0001801834) (Subject)

    8/29/24 4:00:27 PM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PRFX
    Leadership Updates

    Live Leadership Updates

    View All

    PainReform Provides Year-End Business Update and Reports Progress Towards Commencing Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief

    HERZLIYA, Israel, March 18, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a year-end business update.  Significant events and achievements during the fourth quarter 2020 and subsequent period: Preparation for the first Phase 3 clinical trial, for patients undergoing bunionectomy surgery, is expected to begin by mid-2021Announced the engagement of Lotus Clinical Research as the Company’s clinical research organization to conduct the Phase 3 clinical trials under the leadership of Dr. Neil SinglaAnnounced the appointment of Ri

    3/18/21 9:15:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PainReform Appoints Rita Keynan as Vice President of Pharmaceutical Operations

    HERZLIYA, Israel, Jan. 06, 2021 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced the appointment of Rita Keynan as Vice President of Pharmaceutical Operations. Mrs. Keynan brings over 25 years of managerial experience in the pharmaceutical industry. Mrs. Keynan has been responsible for drug development from early phase trials through NDA filings, including managing all chemistry, manufacturing and control (CMC) activities supporting product development, clinical supplies, scale-up, regulatory submissions and commercial manufacturing

    1/6/21 8:30:00 AM ET
    $PRFX
    Biotechnology: Pharmaceutical Preparations
    Health Care